IMR Press / CEOG / Volume 42 / Issue 1 / DOI: 10.12891/ceog1845.2015

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Case Report
Successful pregnancy and breastfeeding in a woman with mucopolysaccharidosis type I while receiving laronidase enzyme replacement therapy
Show Less
1 Dipartimento di Tutela della Donna e della Vita Nascente, Pediatria; Università Cattolica del Sacro Cuore, Rome (Italy)
2 Laboratorio di Neonatologia, Dipartimento di Tutela della Donna e della Vita Nascente, Pediatria;
3 Università Cattolica del Sacro Cuore, Rome (Italy); 3Genzyme, a Sanofi company, Cambridge, MA (USA)
Clin. Exp. Obstet. Gynecol. 2015, 42(1), 108–113;
Published: 10 February 2015
The authors describe the first mother-infant pair to complete an on-going, prospective, open-label, Phase 4 trial (ALID 01803, NCT00418821) determining the safety of laronidase enzyme replacement therapy (ERT) in pregnant women with mucopolysaccharidosistype I (MPS I) and their breastfed infants. The mother, a 32-year-old with attenuated MPS I (Scheie syndrome), received laronidasefor three years and continued treatment throughout her second pregnancy and while lactating. A healthy 2.5 kg male wasdelivered by elective cesarean section at 37 weeks. He was breastfed for three months. No laronidase was detected in breast milk. Theinfant never developed anti-laronidase IgM antibodies, never had inhibitory antibody activity in a cellular uptake assay, and always hadnormal urinary glycosaminoglycan (GAG) levels. No drug-related adverse events were reported. At 2.5 years of age, the boy is healthywith normal growth and development. In this first prospectively monitored mother-infant pair, laronidase during pregnancy and breastfeedingwas uneventful.
Mucopolysacccharidosis type I
Scheie syndrome
Back to top